Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee
NCT02609126 is registered in ClinicalTrials.gov with Eupraxia Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee
- Lead sponsor
- Eupraxia Pharmaceuticals Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2016
- Completion date
- December 28, 2017
- Enrollment
- 32 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.